Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

Based on 134 first isolates · ICU · Skin / wound infection · 2025-04-06 → 2026-04-05
Intensive care unit
Per-organism detail: ICU wound resistance view → ⚠ 3 active alerts in ICU: they are taken into account below. View alerts →
No single agent reaches 80 % coverage for this profile. Highest coverage without active warning:
vancomycin 57 % (49 %–66 %)
Best two-drug combination: ciprofloxacin + vancomycin covers 93 % (88 %–96 %)
Take cultures before treatment; consider a combination and discuss with infectious diseases if the patient is severely ill.
Not covered: Pseudomonas aeruginosa (13 %), Escherichia coli (12 %), Proteus mirabilis (7 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
vancomycin VAN
trend · Staphylococcus aureus Gram-positive only
57 %
83 %
n = 12
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
⚠ Staphylococcus aureus: 63 % resistant in the last 4 weeks (baseline 10 %)
42 %
33 %
n = 12
meropenem MEM
trend · Pseudomonas aeruginosa reserve
⚠ Active MRSA cluster (10 cases): β-lactams do not cover MRSA
41 %
17 %
n = 12
piperacillin-tazobactam TZP
trend · Pseudomonas aeruginosa broad spectrum
⚠ Active MRSA cluster (10 cases): β-lactams do not cover MRSA
40 %
17 %
n = 12
36 %
17 %
n = 12
ceftriaxone CRO
trend · Escherichia coli
⚠ Active MRSA cluster (10 cases): β-lactams do not cover MRSA
29 %
17 %
n = 12
⚠ Active MRSA cluster (10 cases): β-lactams do not cover MRSA
28 %
17 %
n = 12
⚠ Active MRSA cluster (10 cases): β-lactams do not cover MRSA
19 %
8 %
n = 12
⚠ Active MRSA cluster (10 cases): β-lactams do not cover MRSA
10 %
0 %
n = 12
mecillinam MEC
not for this site
⚠ Active MRSA cluster (10 cases): β-lactams do not cover MRSA
0 %
0 %
n = 12
trimethoprim TMP
not for this site
0 %
0 %
n = 12
nitrofurantoin NIT
not for this site
0 %
0 %
n = 12

Most likely organisms for this profile

Staphylococcus aureus
49 %
Pseudomonas aeruginosa
13 %
Escherichia coli
12 %
Enterococcus faecalis
9 %
Proteus mirabilis
7 %
Klebsiella pneumoniae
6 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.